Targeted treatments and immunotherapy for Haematological Cancers – May 2026
Virtual delivery via MS TeamsHaematological cancers differ from solid tumours in many ways: in the mutations that drive them, their interactions with their environment, and the treatments that are effective against them. This course introduces the biology, behaviours and genetics of this diverse group of diseases with a focus on the features we can now target and the mechanisms of action of the various treatments
LEO Programme – CH58 – May 2026 (Internal Only)
Eldon Court (ED) – Newcastle upon Tyne, Newcastle Upon Tyne, Tyne and Wear, NE1 7YEPlease note our Leading an Empowered Organisation™ (LEO) programme is a development opportunity for nursing, midwifery and allied health professional (NMAHP) staff working at Newcastle Hospitals only
Introduction to managing Benign paroxysmal positional vertigo (BPPV) – 11 June 2026 PM
Eldon Court (ED) – Newcastle upon Tyne, Newcastle Upon Tyne, Tyne and Wear, NE1 7YEBenign Paroxysmal Positional Vertigo (BPPV) is one of the most common causes of dizziness and imbalance, significantly increasing fall risk - especially in older adults. Join our hands on practical course to help you demystify the physiology and management of BPPV with a focus on practical skills and case scenarios to help you to gain confidence to assess and treat patients.
LEO Programme – CH59 – June 2026 (Internal Only)
Eldon Court (ED) – Newcastle upon Tyne, Newcastle Upon Tyne, Tyne and Wear, NE1 7YEPlease note our Leading an Empowered Organisation™ (LEO) programme is a development opportunity for nursing, midwifery and allied health professional (NMAHP) staff working at Newcastle Hospitals only
Demystifying the Science Behind Systemic Treatments for Prostate, Bladder and Kidney Cancers – July 2026
Virtual delivery via MS TeamsDuring this introduction to the science behind a wide variety of systemic treatments given to people with prostate, bladder, or kidney cancer, Dr Elaine Vickers will discuss current hormone therapies, immunotherapy and targeted treatments.
Targeted treatments and immunotherapy for Lung Cancer – September 2026
Virtual delivery via MS TeamsA focus on modern systemic treatments for non-small cell lung cancer (NSCLC) as well as the gene faults that drive many NSCLCs; the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET, and RET; the immune system and checkpoint inhibitor group of immunotherapies, including PD-1, PD-L1 and CTLA-4 targeted antibody therapies